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We read with great interest the paper “Combined preoperative 
platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic 
factor in patients with resected pancreatic cancer” published in Hepatobiliary & 
Pancreatic Diseases International [1]. The authors reviewed the oncological outcomes 
of 103 patients with pancreaticoduodenectomy, distal pancreatectomy or total 
pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). They correlated the 
overall (OS) and disease specific survival (DSS) of these patients with 
platelet-to-lymphocyte ratio (PLR) and carbohydrate antigen 19-9 (CA 19-9) level 
which were measured within one month prior to surgery. The authors used cutoff values 
of 129.1 for PLR and 74.0 U/mL for CA 19-9. The worst prognosis was found for 
patients with high PLR and high CA 19-9 (five-year OS=11.9%, DSS=16.8%). An 
intermediate survival for patients with either one of the two factors was decreased 
(five-year OS=31.9% and DSS=36.4%), and the best prognosis for patients with low 
PLR and low CA 19-9 (five-year OS=44.0% and DSS=47.7%). 
Incidence of pancreatic cancer is continuously increasing globally with a 33.6% 
increase between 1990 and 2016; 19.7% of this increase is due to the increase of aged 
population, 12.4% due to population growth, and 1.5% due to change in incidence rate 
[2]. Despite significant improvements of the surgical techniques, intensive care, 
adjuvant and neoadjuvant chemoradiotherapy regimen and imaging, pancreatic cancer 
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continues to be one of the most lethal human malignancies [3–6]. There are significant 
efforts in the fundamental and clinical research to find genetic and epigenetic 
biomarkers with increased accuracy to guide therapy in patients with PDAC [7, 8]. CA 
19-9 and PLR are easily accessible, informative, and seem to correlate with prognosis 
in patients with surgical resection for pancreatic cancer.  
CA 19-9, also termed as sialyl Lewis-a (sLea), is the most commonly used and 
largely studied serum tumor marker for diagnosis and post-therapy surveillance in 
patients with pancreatic cancer [9]. It is expressed on the surface of the cancer cells. CA 
19-9 is accumulating during carcinogenesis due to epigenetic silencing of the gene for 
2-6 sialyl transferase [10]. The CA 19-9 was reported to be also useful in predicting 
prognosis in patients with pancreatic cancer [11]. Hata et al. analyzed 269 resected 
patients with PDAC and revealed that lymph node metastasis (P<0.0001) and 
postoperative CA 19-9 > 37 U/mL (P<0.0001) were independent predictors of poor 
survival. Patients with higher postoperative CA 19-9 levels had a higher rate of 
microscopically positive resection margins, hepatic and peritoneal recurrences [12]. 
Postoperative CA 19-9 level seems to be a better prognostic factor than its preoperative 
measurement, and radical surgery should be offered irrespective of its initial value [12]. 
Hayasaki et al. analyzed 307 patients undergoing surgical resection after neoadjuvant 
chemoradiotherapy [13]. They found that DSS was significantly poorer in resectable 
patients with pretreatment CA 19-9 > 500 U/mL, and that CA 19-9 was not associated 
with DSS in resected patients with borderline resectable or locally advanced disease 
[13].  
The inflammation represents a crossroad between intrinsic factors (genome 
stability genes, oncogenes, tumor suppressors) and local microenvironment (immune 
factors and stromal tissue) contributing to carcinogenesis and cancer progression 
[14–16]. Very refined prognostic biomarkers, such as IL-2, IL-6, IL-10, vascular 
endothelial growth factor (VEGF) and transforming growth factor (TGF), are 
investigated in scientific research [17, 18]. However, important information about 
systemic inflammation, to help decision making in daily clinical practice can be 
obtained from routine blood samples (PLR, neutrophil-to-lymphocyte ratio [NLR], 
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C-reactive protein) [1,19]. A meta-analysis of 34 studies including 7105 patients with 
pancreatic cancer revealed that high PLR and NLR were defined as values from 150 to 
200, and 2 to 5, respectively [20]. They found a significant correlation between high 
PLR (HR=1.143, 95% CI: 1.037 to 1.259) and NLR (HR=1.737, 95% CI: 1.502 to 
2.009) and poor survival. Both parameters had no prognostic role in patients who 
underwent chemoradiotherapy [20]. Song et al. conducted a meta-analysis of 8 studies 
including 1904 patients with pancreatic cancer [21], and found that the PLR was 
associated with decreased OS (HR=1.22, 95% CI: 1.04 to 1.43, P = 0.02), especially in 
Asian studies, patients with metastatic disease and for values of PLR over 150.  
In conclusion, CA 19-9 and platelet-to-lymphocyte ratio are easily accessible, 
informative, and correlate with prognosis in patients with surgical resection for 
pancreatic cancer. However, studies investigating these biomarkers present a 
significant heterogeneity, and should be validated by prospectively collected data.  
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